29 results
424B3
VTYX
Ventyx Biosciences Inc
1 May 24
Prospectus supplement
4:06pm
leverage the substantial experience of our team in immunology to identify important new targets and to develop differentiated therapeutics against … these targets. Our clinical product candidates address therapeutic indications with substantial commercial opportunity for novel small molecules
S-3
VTYX
Ventyx Biosciences Inc
9 Apr 24
Shelf registration
5:07pm
with significant unmet need. We leverage the substantial experience of our team in immunology to identify important new targets and to develop differentiated … therapeutics against these targets. Our clinical product candidates address therapeutic indications with substantial commercial opportunity for novel small
POS AM
VTYX
Ventyx Biosciences Inc
27 Feb 24
Prospectus update (post-effective amendment)
5:55pm
important new targets and to develop differentiated therapeutics against these targets. Our clinical product candidates address therapeutic … new targets and to develop differentiated therapeutics against these targets. Our clinical product candidates address therapeutic indications
POSASR
hzfwwuz
13 Feb 24
Automatic shelf registration (post-effective amendment)
4:09pm
POS AM
ddmmkk0vkfxx t4u
20 Dec 22
Prospectus update (post-effective amendment)
4:58pm
S-3ASR
fwewdm 4dks1re3f3
20 Dec 22
Automatic shelf registration
4:10pm
8-K
EX-99.1
qnieya
30 Nov 22
Regulation FD Disclosure
4:37pm
424B3
c8n4u bcm
4 Oct 22
Prospectus supplement
8:58pm
8-K
EX-99.2
cdy5fpb0e5x
29 Jun 22
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
8:30am
8-K
EX-99.1
e131neol
9 May 22
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
8:07am
10-K
ob1gch13
23 Mar 22
Annual report
5:49pm